Global Primary Myelofibrosis (PMF) Market Growth 2025-2031
Description
The global Primary Myelofibrosis (PMF) market size is predicted to grow from US$ 164 million in 2025 to US$ 290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031.
Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation. The statistic scope is primary myelofibrosis drug in this report.
United States market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Primary Myelofibrosis (PMF) players cover GSK, AbbVie, Novartis, Celgene, Grunenthal, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Primary Myelofibrosis (PMF) Industry Forecast” looks at past sales and reviews total world Primary Myelofibrosis (PMF) sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Myelofibrosis (PMF) sales for 2025 through 2031. With Primary Myelofibrosis (PMF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Myelofibrosis (PMF) industry.
This Insight Report provides a comprehensive analysis of the global Primary Myelofibrosis (PMF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Myelofibrosis (PMF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Myelofibrosis (PMF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Myelofibrosis (PMF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Myelofibrosis (PMF).
This report presents a comprehensive overview, market shares, and growth opportunities of Primary Myelofibrosis (PMF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
JAK 1
JAK 2
Others
Segmentation by Application:
Adults
Children
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
AbbVie
Novartis
Celgene
Grunenthal
Incyte
CTI BioPharma
Bristol Myers Squibb
Suzhou Zelgen Biopharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Primary Myelofibrosis (PMF) market?
What factors are driving Primary Myelofibrosis (PMF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Primary Myelofibrosis (PMF) market opportunities vary by end market size?
How does Primary Myelofibrosis (PMF) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation. The statistic scope is primary myelofibrosis drug in this report.
United States market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Primary Myelofibrosis (PMF) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Primary Myelofibrosis (PMF) players cover GSK, AbbVie, Novartis, Celgene, Grunenthal, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Primary Myelofibrosis (PMF) Industry Forecast” looks at past sales and reviews total world Primary Myelofibrosis (PMF) sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Myelofibrosis (PMF) sales for 2025 through 2031. With Primary Myelofibrosis (PMF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Myelofibrosis (PMF) industry.
This Insight Report provides a comprehensive analysis of the global Primary Myelofibrosis (PMF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Myelofibrosis (PMF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Myelofibrosis (PMF) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Myelofibrosis (PMF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Myelofibrosis (PMF).
This report presents a comprehensive overview, market shares, and growth opportunities of Primary Myelofibrosis (PMF) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
JAK 1
JAK 2
Others
Segmentation by Application:
Adults
Children
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
AbbVie
Novartis
Celgene
Grunenthal
Incyte
CTI BioPharma
Bristol Myers Squibb
Suzhou Zelgen Biopharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Primary Myelofibrosis (PMF) market?
What factors are driving Primary Myelofibrosis (PMF) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Primary Myelofibrosis (PMF) market opportunities vary by end market size?
How does Primary Myelofibrosis (PMF) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
88 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Primary Myelofibrosis (PMF) by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Primary Myelofibrosis (PMF) by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
